Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Invested Capital (2016 - 2025)

UroGen Pharma's Invested Capital history spans 10 years, with the latest figure at $19.5 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 321.81% year-over-year to $19.5 million; the TTM value through Dec 2025 reached $19.5 million, up 321.81%, while the annual FY2025 figure was $19.5 million, 321.81% up from the prior year.
  • Invested Capital reached $19.5 million in Q4 2025 per URGN's latest filing, up from -$115.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $76.5 million in Q1 2021 to a low of -$138.4 million in Q2 2023.
  • Average Invested Capital over 5 years is -$31.4 million, with a median of -$40.5 million recorded in 2022.
  • Peak YoY movement for Invested Capital: tumbled 1162.18% in 2022, then skyrocketed 321.81% in 2025.
  • A 5-year view of Invested Capital shows it stood at $8.4 million in 2021, then crashed by 1162.18% to -$89.4 million in 2022, then rose by 27.02% to -$65.2 million in 2023, then skyrocketed by 86.5% to -$8.8 million in 2024, then surged by 321.81% to $19.5 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Invested Capital are $19.5 million (Q4 2025), -$115.4 million (Q3 2025), and -$93.4 million (Q2 2025).